Rgenta Therapeutics inks deal with GSK

Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK (LSE: GSK).

The alliance aims to advance the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology, and marked the second deal in the space of 24 hours for GSK, which has just entered into collaboration with DualityBio.

"We are excited about Rgenta's differentiated approach to discover and develop oral small molecule splice modulators for high-value targets," said Dr Christopher Austin, senior vice president, research technologies at GSK, adding: "We are dedicated to partnering with leading companies to complement our existing expertise in RNA-targeting medicines and look forward to advancing this promising modality to more patients with difficult-to-treat diseases."